If you would want to account for biological diversity when doing drug trials you would require pre-existing conditions to be as prevalent in the population that you test in your drug trial. Saying that you have at least X percent obese people would likely give you more clinical knowledge than requiring at least X percent to be Native Americans.
Big Pharma generally selects participants to have less preexisting conditions and take less other medication than the general population. In the end FDA, requirements for drug legalization have positive advantages but also make drug trials and new drugs more expensive.
There are both arguments to be more for more FDA and for less FDA regulation. In this case, I think it’s worth noting that we have a Trump appointee defending some DEI regulatory requirements.
If you would want to account for biological diversity when doing drug trials you would require pre-existing conditions to be as prevalent in the population that you test in your drug trial. Saying that you have at least X percent obese people would likely give you more clinical knowledge than requiring at least X percent to be Native Americans.
Big Pharma generally selects participants to have less preexisting conditions and take less other medication than the general population. In the end FDA, requirements for drug legalization have positive advantages but also make drug trials and new drugs more expensive.
There are both arguments to be more for more FDA and for less FDA regulation. In this case, I think it’s worth noting that we have a Trump appointee defending some DEI regulatory requirements.